Treatment of Refractory Thrombocytopenia

Initial Considerations and Treatment Options

The American Society of Hematology recommends TPO-receptor agonists, such as romiplostim or eltrombopag, as the preferred treatment option for patients with refractory thrombocytopenia who have failed first- and second-line therapies, with response rates of 79-88% and favorable safety profiles allowing indefinite use 1, 2
For patients with platelet counts as low as 10×10⁹/L, the risk-benefit ratio should be discussed, as some patients can tolerate severe thrombocytopenia with near-normal quality of life and may opt to avoid toxic treatments 1, 3, 4

Romiplostim has a response rate of 88% in non-splenectomized patients and 79% in splenectomized patients, with a time to response of 1-4 weeks 1, 2, 3
Eltrombopag has a response rate of 70-81% depending on the dose, with a time to response of 2-3 months 1, 6

Combination chemotherapy with cyclophosphamide, prednisone, vincristine, and either azathioprine or etoposide has a response rate of 68% overall, with 42% achieving complete response 1, 3, 4, 7
Campath-1H (alemtuzumab) has a response rate of 67% initial response, but all but 1 patient relapsed within 24 months 1, 2

Hematopoietic stem cell transplantation has a response rate of 43% and is warranted only in patients with severe chronic refractory ITP with bleeding complications unresponsive to all other modalities 1, 7

TPO-agonists should not be abruptly discontinued, and patients should be monitored for thrombosis risk, particularly those receiving TPO-agonists, as treatment-related thrombotic events occur in 2-3% of patients 6